Leukemia Clinical Trials in New York

Showing 621-640 of 1,787 trials

Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

NCT05424029

The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.

Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center200 participantsStarted Jun 2022

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Montvale, New Jersey, United States +4 more locations

TERMINATEDPhase 1< 1 mile

A Study to Investigate LYL797 in Adults With Solid Tumors

NCT05274451

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.

Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more

Lyell Immunopharma, Inc.57 participantsStarted Mar 2022

Scottsdale, Arizona, United States • Santa Monica, California, United States • New Haven, Connecticut, United States +15 more locations

Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

A Study to Investigate LYL797 in Adults With Solid Tumors

Leukemia Trials in Other Cities

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Pembrolizumab for Advanced NSCLC and PS 2-3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

ALL Adult Consortium Trial: Adult ALL Trial

AVID100 in Advanced Epithelial Carcinomas

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Medical Access Program for Patritumab Deruxtecan

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Early Allergen System Experience

MAGIC Ruxolitinib for aGVHD

A Study to Investigate LYL845 in Adults With Solid Tumors

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Other Conditions in New York